Approval in CSU for children two to 11 years of age is based on data from the LIBERTY-CUPID clinical study program, including an extrapolation of efficacy data showing that Dupixent significantly ...
Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of ...
Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous ...
Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of efficacy data showing that Dupixent significantly reduce ...
In this video, Aaron Mark Drucker, MD, ScM, FRCPC, discusses his talk on the relative efficacy of small molecule, oral JAK ...
In early April 2026, Regeneron Pharmaceuticals received U.S. FDA approval to extend EYLEA HD dosing intervals up to every 20 ...
A Narrandera family is calling on the Federal Government to expand access to a medicine they say has allowed their ...
AstraZeneca's IL-33-targeting antibody tozorakimab has made the grade in two phase 3 chronic obstructive pulmonary disease (COPD) trials, raising the prospects of a class that has recorded some ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results